About CBR

Since the company’s founding, Cord Blood Registry® (CBR®) has led the industry in technical innovations
and provided families with access to current
treatments and experimental stem cell therapies for
conditions that have no cure.

Weng family
Banked 2012, 2014

Company Overview

Cord Blood Registry (CBR) is the world’s largest newborn stem cell company. Founded in 1992, CBR is entrusted by parents with storing samples from more than 600,000 children. CBR is dedicated to advancing the clinical application of cord blood and cord tissue stem cells by partnering with institutions to establish FDA-regulated clinical trials for conditions that have no cure today.

CBR has helped more than 400+ families use their cord blood stem cells for established and experimental medical treatments, more than any other family cord blood bank. CBR’s goal is to expand the potential scope of newborn stem cell therapies that may be available to patients and their families.

Cord Blood Registry is headquartered in South San Francisco, California. CBR’s owned 80,000 square foot laboratory is located in Tucson, Arizona.

Cord Blood Registry is a registered trademark of CBR Systems, Inc.

History of Quality

CBR maintains standards for cellular therapy services through AABB accreditation, FDA-registration, and CLIA certification.

CBR has the longest history of accreditation with the AABB (formerly known as the American Association of Blood Banks) and the company’s quality standards have been recognized through ISO 9001:2008 certification — the global business standard for quality.

Advancing Medicine

A pioneer in newborn stem cell collection and cryopreservation, CBR believes in the power of newborn stem cells to improve lives today and their potential to revolutionize treatment for many conditions in the future.

CBR is the first family newborn stem cell bank to partner with leading research institutions to establish FDA-regulated clinical trials exploring the potential regenerative ability of stem cells to help treat conditions that have no cure today, including: acquired hearing loss, autism, cerebral palsy, and pediatric stroke. In fact, 73% of the stem cell units released by CBR have been used for experimental regenerative therapies – more than any other family cord blood bank in the world.

Innovative

CBR created the world’s only collection device designed specifically for cord blood stem cells. CBR’s CellAdvantage® Collection Kit contains everything the healthcare provider needs to help maximize the cord blood collection volume.

CBR developed a crush-resistant, temperature protected, and electronically tracked kit that actively transforms into a cube to encase the blood and/or tissue collection, helping to ensure that it is protected and delivered safely. On average, the transport time from the hospital to CBR’s lab is 19 hours. CBR processes cord blood using the AutoXpress® Platform* (AXP®) — a fully automated, functionally closed stem cell processing technology. CBR has the industry’s highest published average cell recovery rate of 99%.1-3,8

*AXP and AutoXpress are registered trademarks of ThermoGenesis Corp

CBR Executive Team

A team is only as strong as its leadership. Our commitment to helping families starts at the top with our executives.

Peter Bawin
Peter Bawin
Senior Vice President and General Manager for Cord Blood Registry

Peter Bawin serves as senior vice president and general manager for Cord Blood Registry (CBR). Mr. Bawin joined CBR in 2009 and held leadership roles of increasing responsibility before the company was acquired by AMAG in 2015. With more than 15 years of healthcare, pharmaceutical, consumer, digital marketing and sales experience, Mr. Bawin previously held product management roles within Mylan's EpiPen business and began his career as a pharmaceutical sales representative with the allergy and cardiovascular franchises at Schering-Plough. Mr. Bawin holds a Bachelor of the Arts degree from Miami University and a Master of Business Administration degree from the University of Denver.

Heather Brown
Heather Brown
Vice President, Scientific and Medical Affairs

Heather Brown has been with CBR since 2001 and has more than 20 years of clinical and business experience in the healthcare and biotech industries. Heather is a board certified genetic counselor with extensive experience in prenatal, pediatric, and cancer genetics. Heather has led a number of new business development and healthcare marketing initiatives during her tenure at CBR. In her current role, Heather is primarily responsible for research partnerships, clinical trial management, and medical need-based programs. Heather holds a B.A. and M.S. in Health and Medical Sciences from the University of California at Berkeley.

Kristen Swingle
Kristen Swingle
Vice President, Consumer Sales and Operations

Kristen Swingle has been responsible for overseeing all operations at CBR’s laboratory in Tucson, Arizona, since 2007. Kristen has a strong background in process implementation, continuous improvement and leadership development. During her tenure at CBR, Kristen served as the project lead for the implementation of AXP processing at CBR and was integral in the implementation of CBR’s cord tissue product offering. In her current role, Kristen is primarily responsible for serving our clients through her oversight of our client sales and service and laboratory operations teams. Kristen holds a B.S. in Biology and a M.S. in Medical Sciences. Additionally, Kristen serves as Vice Chair of the Arizona BioIndustry Association (AZBio) Board of Directors.

Sign up for free information and special offers. Ready to enroll? Start here, too.